the half-life question that gets asked weekly, answered properly
the half-life question that gets asked weekly, answered properly. Making the case below, and I expect to lose some of it in the comments. Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not…
incretin effect first, then everything else in this board makes sense
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
Correcting my own comment: I attributed that to the GIP arm and the paper attributes it to the GLP-1 arm.
receptor distribution is why the side effects are where they are
Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.
Is that from a human study or a preclinical model?
the peripheral and central stories are not in competition
Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.